Bill > HR1143

This bill seeks to expand Medicare coverage for in-home administration of intravenous immune globulin (IVIG), a medical treatment involving the infusion of antibodies collected from donated blood plasma. Specifically, the bill will modify existing Medicare regulations to include coverage for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), two neurological conditions, starting January 1, 2027. Currently, Medicare only covers in-home IVIG administration for patients with primary immune deficiency diseases. The bill also grants the Secretary of Health and Human Services the authority to vary payment rates for IVIG administration based on the specific medical condition being treated, which will be determined through a formal notice and comment rulemaking process. This change aims to increase access to home-based treatment for patients with these neurological disorders, potentially improving their quality of life by allowing them to receive complex medical treatments in a more comfortable and convenient setting.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/1143/all-info